| Title | CT-guidance interstitial (125)Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors |
| Authors | Cao, Qianqian Wang, Hao Meng, Na Jiang, Yuliang Jiang, Ping Gao, Yang Tian, Suqing Liu, Chen Yang, Ruijie Wang, Junjie Zhang, Kaixian |
| Affiliation | Peking Univ, Hosp 3, Dept Radiat Oncol, Ctr Canc, Beijing 100191, Peoples R China. Peking Univ, Hosp 3, Dept Radiol, Beijing 100191, Peoples R China. Tengzhou Cent Peoples Hosp, Ctr Canc, Tengzhou City 277500, Shangdong Provi, Peoples R China. Peking Univ, Hosp 3, Dept Radiat Oncol, Ctr Canc, 49 North Garden Rd, Beijing 100191, Peoples R China. |
| Keywords | Brachytherapy I-125 seed implantation Primary spine tumors CT-guided Outcome DOSE-RATE BRACHYTHERAPY PERCUTANEOUS VERTEBROPLASTY CLINICAL-EXPERIENCE SINGLE INSTITUTION CORD COMPRESSION RADIOSURGERY METASTASES IMPLANTATION SURGERY CANCER |
| Issue Date | 2014 |
| Publisher | radiation oncology |
| Citation | RADIATION ONCOLOGY.2014,9. |
| Abstract | Background: Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided I-125 seed brachytherapy for recurrent paraspinous and vertebral primary tumors. Methods: From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of I-125 seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D-90 of I-125 seeds were 90-183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 months (median 19 months). The local control rate was calculated by the Kaplan-Meier method. Results: For 5 Chondrosarcomas, the 1-, 2-, 3-year local control rates were 75%, 37.5%, and 37.5%, respectively, with a median of 34 months (range, 4-39 months). For 4 chordomas, the local control rate was 50% with a median follow-up of 13 months (range, 3-17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation, without more than Frankel grade 3 radiation myelopathy. Conclusions: Percutaneous I-125 seed implantation can be an alternative or retreatment for recurrent spinal primary tumors. |
| URI | http://hdl.handle.net/20.500.11897/161283 |
| ISSN | 1748-717X |
| DOI | 10.1186/s13014-014-0301-8 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 第三医院 |
